S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Galectin Therapeutics Stock Forecast, Price & News

-0.14 (-5.17%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
96,976 shs
Average Volume
1.47 million shs
Market Capitalization
$152.51 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive GALT News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Galectin Therapeutics logo

About Galectin Therapeutics

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.12 per share


Net Income
$-23.47 million
Pretax Margin




Free Float
Market Cap
$152.51 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.30 out of 5 stars

Medical Sector

273rd out of 1,392 stocks

Pharmaceutical Preparations Industry

120th out of 670 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions

Is Galectin Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Galectin Therapeutics stock.
View analyst ratings for Galectin Therapeutics
or view top-rated stocks.

How has Galectin Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Galectin Therapeutics' stock was trading at $1.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GALT shares have increased by 29.1% and is now trading at $2.57.
View which stocks have been most impacted by COVID-19

When is Galectin Therapeutics' next earnings date?

Galectin Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 30th 2022.
View our earnings forecast for Galectin Therapeutics

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) released its quarterly earnings results on Monday, November, 15th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04.
View Galectin Therapeutics' earnings history

What price target have analysts set for GALT?

1 brokers have issued 1 year target prices for Galectin Therapeutics' shares. Their forecasts range from $14.00 to $14.00. On average, they expect Galectin Therapeutics' share price to reach $14.00 in the next year. This suggests a possible upside of 444.7% from the stock's current price.
View analysts' price targets for Galectin Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Galectin Therapeutics' key executives?

Galectin Therapeutics' management team includes the following people:
  • Joel Lewis, President, Chief Executive Officer & Director
  • Jack W. Callicutt, Chief Financial Officer & Secretary
  • Pol F. Boudes, Chief Medical Officer
  • Ezra R. lowe, Executive Director-Clinical
  • Marla Mills-Wilson, Executive Director-Clinical Operations

What other stocks do shareholders of Galectin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Novavax (NVAX), Verastem (VSTM) and Immunomedics (IMMU).

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

Who are Galectin Therapeutics' major shareholders?

Galectin Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.33%), Geode Capital Management LLC (0.91%), Millennium Management LLC (0.59%), Cambridge Investment Research Advisors Inc. (0.28%), Keybank National Association OH (0.17%) and QCI Asset Management Inc. NY (0.09%). Company insiders that own Galectin Therapeutics stock include Fund LP 10X, Gilbert F Amelio and Kevin D Freeman.
View institutional ownership trends for Galectin Therapeutics

Which major investors are selling Galectin Therapeutics stock?

GALT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, Benjamin F. Edwards & Company Inc., BlackRock Inc., Cambridge Investment Research Advisors Inc., Goldman Sachs Group Inc., and Citadel Advisors LLC. Company insiders that have sold Galectin Therapeutics company stock in the last year include Fund LP 10X, and Gilbert F Amelio.
View insider buying and selling activity for Galectin Therapeutics
or view top insider-selling stocks.

Which major investors are buying Galectin Therapeutics stock?

GALT stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Keybank National Association OH, Capstone Investment Advisors LLC, QCI Asset Management Inc. NY, Raymond James & Associates, Wedbush Securities Inc., Commonwealth Equity Services LLC, and Buckingham Strategic Wealth LLC.
View insider buying and selling activity for Galectin Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Galectin Therapeutics?

Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galectin Therapeutics' stock price today?

One share of GALT stock can currently be purchased for approximately $2.57.

How much money does Galectin Therapeutics make?

Galectin Therapeutics has a market capitalization of $152.51 million. The company earns $-23.47 million in net income (profit) each year or ($0.54) on an earnings per share basis.

How many employees does Galectin Therapeutics have?

Galectin Therapeutics employs 6 workers across the globe.

What is Galectin Therapeutics' official website?

The official website for Galectin Therapeutics is www.galectintherapeutics.com.

Where are Galectin Therapeutics' headquarters?

Galectin Therapeutics is headquartered at 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071.

How can I contact Galectin Therapeutics?

Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at (678) 620-3186, via email at [email protected], or via fax at 770-864-1327.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.